A5042064422- Pesticide Residue Analysis and Safety
- Analytical Chemistry and Chromatography
- Analytical Methods in Pharmaceuticals
- Statistical Methods in Clinical Trials
- Biosimilars and Bioanalytical Methods
- Spectroscopy and Chemometric Analyses
- Computational Drug Discovery Methods
- Optimal Experimental Design Methods
- Advanced Statistical Process Monitoring
- Scientific Measurement and Uncertainty Evaluation
- Clinical Laboratory Practices and Quality Control
- Fault Detection and Control Systems
- Microfluidic and Capillary Electrophoresis Applications
- Blind Source Separation Techniques
- Advanced Chemical Sensor Technologies
- Advanced Statistical Methods and Models
- Viral Infectious Diseases and Gene Expression in Insects
- Animal testing and alternatives
- Antibiotics Pharmacokinetics and Efficacy
- Protein purification and stability
- Healthcare Systems and Practices
- Agriculture and Rural Development Research
- Analytical chemistry methods development
- Forecasting Techniques and Applications
- Neurogenetic and Muscular Disorders Research
University of Liège
2008-2020
Statistics Belgium
1999-2018
Agfa-Gevaert (Belgium)
2011-2012
UCB Pharma (Belgium)
2007-2009
Institut de Recherche Mathématique Avancée
2008
Eli Lilly (United States)
1999-2006
UCLouvain
2005
Novadip (Belgium)
2002-2004
Cranfield University
1999
University of Alberta
1995-1998
Over the last two decades, awareness of negative repercussions flaws in planning, conduct and reporting preclinical research involving experimental animals has been growing. Several initiatives have set out to increase transparency internal validity studies, mostly publishing expert consensus experience. While many points raised these various guidelines are identical or similar, they differ detail rigour. Most them focus on reporting, only few cover planning studies. The aim this systematic...
The concept of quality by design (QbD) has recently been adopted for the development pharmaceutical processes to ensure a predefined product quality. Focus on applying QbD analytical methods increased as it is fully integrated within and especially in process control strategy. In addition, there need switch from traditional checklist implementation method validation requirements approach that should provide high level assurance reliability order adequately measure critical attributes (CQAs)...
Centronuclear myopathies are severe rare congenital diseases. The clinical variability and genetic heterogeneity of these result in major challenges trial design. Alternative strategies to large placebo-controlled trials that have been used other diseases (e.g., the use surrogate markers or historical controls) limitations Bayesian statistics may address. Here we present a model uses each patient's own natural history study data predict progression absence treatment. This prospective...